Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer

AHMAD A. TARHINI, HARIS ZAHOOR, BRIAN MCLAUGHLIN, WILLIAM E GOODING, JOHN C. SCHMITZ, JILL M. SIEGFRIED, MARK A. SOCINSKI and ATHANASSIOS ARGIRIS
Anticancer Research October 2013, 33 (10) 4475-4481;
AHMAD A. TARHINI
1University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tarhiniaa{at}upmc.edu
HARIS ZAHOOR
1University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRIAN MCLAUGHLIN
1University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WILLIAM E GOODING
2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN C. SCHMITZ
2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JILL M. SIEGFRIED
2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARK A. SOCINSKI
1University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATHANASSIOS ARGIRIS
3University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 33 no. 10 4475-4481
PubMed 
24123018

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received September 4, 2013
  • Revision received September 14, 2013
  • Accepted September 16, 2013
  • Published online October 12, 2013.

Copyright & Usage 
Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. AHMAD A. TARHINI1,2⇑,
  2. HARIS ZAHOOR1,
  3. BRIAN MCLAUGHLIN1,
  4. WILLIAM E GOODING2,
  5. JOHN C. SCHMITZ2,
  6. JILL M. SIEGFRIED2,
  7. MARK A. SOCINSKI1,2 and
  8. ATHANASSIOS ARGIRIS3
  1. 1University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  2. 2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.
  3. 3University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A.
  1. Correspondence to: Ahmad A. Tarhini, MD, Ph.D., University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue (555), Pittsburgh, PA 15232, U.S.A. Tel: +1 4126486578, Fax: +1 4126486579, e-mail: tarhiniaa{at}upmc.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 25 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 33, Issue 10
October 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
AHMAD A. TARHINI, HARIS ZAHOOR, BRIAN MCLAUGHLIN, WILLIAM E GOODING, JOHN C. SCHMITZ, JILL M. SIEGFRIED, MARK A. SOCINSKI, ATHANASSIOS ARGIRIS
Anticancer Research Oct 2013, 33 (10) 4475-4481;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
AHMAD A. TARHINI, HARIS ZAHOOR, BRIAN MCLAUGHLIN, WILLIAM E GOODING, JOHN C. SCHMITZ, JILL M. SIEGFRIED, MARK A. SOCINSKI, ATHANASSIOS ARGIRIS
Anticancer Research Oct 2013, 33 (10) 4475-4481;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
  • Google Scholar

More in this TOC Section

  • The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side
  • Gamma Knife Radiotherapy of Brain Metastasis Resection Cavities: Outcome Analysis of a Single-center Cohort
  • Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
Show more Clinical Studies

Similar Articles

Keywords

  • lung cancer
  • panobinostat
  • carboplatin
  • etoposide
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire